Skip to main content
2024 ACRO Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Physician

Resident

NewPractitioner

Session: LUNG: Common and Uncommon Emerging Indications for Thoracic Cancers

2 - Demystifying Uncommon Thoracic Malignancies: Optimizing Management for Thymic Tumors and Pleural Mesothelioma

Saturday, March 16, 2024
8:30 AM – 9:30 AM ET
Location: Grand Ballroom VI-VIII

    Speaker(s)

  • Andreas Rimner, MD (he/him/his)

    Vice Chair
    Department of Radiation Oncology, University of Freiburg
    Loerrach, Baden-Wurttemberg, Germany

    Disclosure(s): AstraZeneca: Consultant/Advisory Board (Terminated, January 19, 2024), Grant/Research Support (Terminated, January 19, 2024), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, January 19, 2024); Boehringer Ingelheim: Grant/Research Support (Terminated, January 19, 2024), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, January 19, 2024); Merck: Consultant/Advisory Board (Terminated, January 19, 2024), Grant/Research Support (Terminated, January 19, 2024), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, January 19, 2024)

    PDF Slides
Disclosure(s):
Andreas Rimner, MD: AstraZeneca: Consultant/Advisory Board (Terminated, January 19, 2024), Grant/Research Support (Terminated, January 19, 2024), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, January 19, 2024); Boehringer Ingelheim: Grant/Research Support (Terminated, January 19, 2024), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, January 19, 2024); Merck: Consultant/Advisory Board (Terminated, January 19, 2024), Grant/Research Support (Terminated, January 19, 2024), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, January 19, 2024)

Learning Objectives:

  • To describe the current indications for radiation therapy in the management of thymic malignancies
  • To describe the current indications for radiation therapy in the management of malignant pleural mesothelioma
  • To list the main toxicities from radiation therapy for thymic malignancies and malignant pleural mesothelioma